Analytical Data
-
基因名
HLA-C*03:04&B2M&KRAS G12D(GADGVGKSAL) Monomer
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
QAV56463.1 (G25-T305)&P61769
-
表达区间
QAV56463.1 (G25-T305)&P61769 (I21-M119)&GADGVGKSAL
-
分子量
55-65 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-C*03:04/B2M/KRAS G12D (GADGVGKSAL) monomeric recombinant protein is pivotal in understanding immune responses against cancer, particularly in the context of Kras-driven tumors. KRAS mutations, such as G12D, are prevalent in various malignancies, including pancreatic and colorectal cancers, and are associated with poor prognosis. The peptide GADGVGKSAL derived from the KRAS G12D mutation is recognized by specific T cells, offering a unique opportunity to develop targeted immunotherapies. By investigating the HLA-C*03:04 molecule, which presents this mutant peptide on the cell surface, researchers can gain insights into how the immune system recognizes and responds to tumor-specific antigens. The recombinant protein serves as a model to study peptide binding affinity, T cell receptor interactions, and overall immune evasion mechanisms employed by tumors. This research could contribute to the design of personalized cancer vaccines and adoptive T cell therapies, harnessing the body’s immune system to target and eliminate cancer cells with KRAS mutations. Understanding the structure, function, and immunogenicity of the HLA-C*03:04/B2M/KRAS G12D complex not only enhances our comprehension of tumor immunology but also paves the way for innovative therapeutic strategies against resistant cancer types.
